



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5776

Title: How to select the optimal treatment for first line metastatic colorectal cancer

Reviewer code: 00039316

Science editor: Gou, Su-Xin

Date sent for review: 2013-09-26 18:20

Date reviewed: 2013-09-27 01:46

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

It was a privilege to review this well written manuscript on the optimal treatment for first line metastatic colorectal cancer. I recommend the addition of two tables that will make the text more comprehensive to our readers. 1. A table that illustrates available patient's prognosis scores and their applicability in clinical practice based on ref 13-15 1. A table that summarizes the efficacy and tolerability of the available intensive first line regimens for mCRC



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5776

Title: How to select the optimal treatment for first line metastatic colorectal cancer

Reviewer code: 00503512

Science editor: Gou, Su-Xin

Date sent for review: 2013-09-26 18:20

Date reviewed: 2013-09-27 08:34

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The review paper by Stein and Bokemeyer is a clear and comprehensive revision of current evidence on first line treatment options for metastatic colorectal cancer. I would just suggest the following minor changes: 1) please expand the section on molecular prognostic factors, which is too short and not very informative. The authors could for example discuss microsatellite instability or circulating tumor cells, which are both emerging as important prognostic factors (see for example PMID: 24042191 and PMID: 23471846) 2) Among future perspectives for predictive-prognostic markers, cancer stem cells should be at least mentioned (see for example PMID: 23409180, PMID: 22231565, PMID: 21926398). 3) Please expand the conclusion by critically summarizing the main treatment options and by discussing unmet needs and fruitful research directions.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5776

Title: How to select the optimal treatment for first line metastatic colorectal cancer

Reviewer code: 00068357

Science editor: Gou, Su-Xin

Date sent for review: 2013-09-26 18:20

Date reviewed: 2013-09-27 10:46

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The author of this review summarized current views and researches on the first line treatment for metastatic colorectal cancer (mCRC). This review has some features as follows: 1. The author has browsed almost all the important research results, and the conclusion of this review is convincing. 2. This review concludes all the drugs and strategies for mCRC. Therefore, the content of this review is comprehensive. 3. Thought in writing is clear. According to Stratification of mCRC, this review introduces the different treatment strategies separately.